Request Demo
Bankrupt Mithra cashes in on remaining assets for $188.2m
Phase 3AcquisitionClinical Result
Mithra’s efforts to extend its cash runway earlier this year were unsuccessful. Image credit: Shutterstock/Nudphon Phuengsuwan.
Mithraafter filing for bankruptcy, Mithra has sold its share in two of its daughter pharmaceutical companies along with rights to its female hormone drug portfolio for €175m ($188.2m).
Recommended Buyer's GuidesMithra
Buyer's Guide
Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
The deal saw Budapest-headquartered pharma company Gedeon Richter buy all of Mithra’s shares in Neuralis and Estetra – both subsidiaries of the struggling women’s health pharmaceutical company. Gedeon Richter also gained assets related to the manufacturing of estetrol.
The funds, after deduction of financial debts, will be used to repay Mithra’s creditors, meaning the sale does not create any value for the shareholders of Mithra Pharmaceuticals, according to a 10 June press release.
Belgium-based Mithra has faced severe financial difficulties in the past few years with share prices tanking by more than 90%. Efforts to extend its cash runway, which included raising $13.7m by selling its stake in Mayne Pharma, were unsuccessful, forcing the company to file for bankruptcy and siphon off its remaining holdings.
The transfer will see Gedeon Richter gain rights toGedeon Richterlle (estetroMithra drospirenoneNeuralisted aEstetratellis and Drovelis in the US and EU respectively. Estelle netted Mithra €2.6mGedeon Richterhalf of 2023.estetrol
See Also:NPX-267 by NextPoint Therapeutics for Triple-Negative BreastMithrar (TNBC): Likelihood of ApprovalMithra Pharmaceuticals
NPX-267 by NexMithra Therapeutics for Non-Small Cell Lung Cancer: Likelihood of ApprovalMayne Pharma
Gedeon Richter will also take on development duties MithrathrEstelleopestetrol-E4entdrospirenoneonesta which prNextstellistive DrovelisPhase III results in mid-2023. The orally adminMithrad estetrol (E4) hormone therapy is slated for US approval in 2024 and EU approval in 2025.
Mithra saNPX-267 “alNextPoint TherapeuticsrsonnTriple-Negative Breast Cancer (TNBC)es will be able to pursue their activities with Gedeon Richter,” along with 17 other employees who have been offered jobs by the latter company.
Two of Mithra’s other properties – Novalon, a long-acting drug specialist entity it acquired in 2015, and a contract development and manufacturing organisation (CDMO) facility – remain unaffected by the deal with Gedeon Richter and stay under protection. Mithra said it expects offers to come in by mid-month subject to judicial protection measures being extended.
NPX-267atemNextPoint Therapeuticse annNon-Small Cell Lung Cancer Mithra stated its employees’ research and future progress “will outlive Mithra and will continue under a different banner from now on. We all hope that these efforts will lead to the development of new solutions that will benefit as many people as possible.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.